Enveric BiosciencesENVB
ENVB
About: Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Employees: 26
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
6% more capital invested
Capital invested by funds: $307K [Q2] → $326K (+$18.9K) [Q3]
1.45% more ownership
Funds ownership: 6.53% [Q2] → 7.97% (+1.45%) [Q3]
0% more funds holding
Funds holding: 17 [Q2] → 17 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for ENVB.
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 12,133,856 (the ‘856 patent) and 12,138,276,(the ‘276 patent) bringing the total number of issued patents supporting.
Neutral
Business Wire
4 weeks ago
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog further supporting the oral bioavailability and targeted non-hallucinogenic profile of EB-003. The PK studies demonstrate.
Neutral
Business Wire
1 month ago
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. “The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge.
Neutral
Business Wire
1 month ago
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-licensing the Company's EVM201 program, including drug candidate EB-002. Pursuant to the terms of licensing agreement,.
Neutral
Business Wire
1 month ago
Enveric Biosciences Announces Broad Range of Patent Issuances
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office. The U.
Neutral
Business Wire
2 months ago
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced positive results for preclinical safety and pharmacology studies, which evaluated off-target interactions of its lead drug candidate, EB-003, and confirmed selective activity with desired serotonergic neurorec.
Neutral
Business Wire
2 months ago
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company's identification of EB-003 as its lead development candidate based on preclinical data suggesting the compound exhibits promising anxiolytic and anti-depre.
Neutral
Business Wire
2 months ago
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that research highlighting the Company's lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,N-Dimethyltryptamine.
Neutral
Business Wire
3 months ago
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024. During the presentation, Dr. Tucker will discuss the development of novel neuroplastogen.
Neutral
Business Wire
4 months ago
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology (“Aries”), a developer of encapsulation technologies, today announced that Patent No. 12,059,393 was issued on August 13, 2024, to Enveric's wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”). We believe the newly issued intellectual property stren.
Charts implemented using Lightweight Charts™